Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer

M. Marzola, G. Parma, C. Bonazzi, N. Colombo, A. Maneo, M. R. Pittelli, C. Mangioni

Research output: Contribution to journalArticlepeer-review


Objective: To evaluate the anti-tumour activity and toxicity of ifosfamide (5 g/m 2 continuous infusion) and mitoxantrone (10 mg/m 2) given in combination every 3 weeks in patients with ovarian cancer resistant to at least two previous regimens which included platinum. Patients and methods: Additional eligibility criteria were an ECOG performance status ≤2 and measurable disease. Of 47 patients entered in the study, 8 were defined as platinum-resistant and 39 as potentially sensitive according to Markman's criteria. Thirty-five patients had also received paclitaxel as last treatment before entering this study. Tumour response was evaluated every three cycles. Results: One complete and 11 partial responses were reported, for an overall response rate of 25% (95% CI: 14%-40%). Three of the partial responders were resistant to platinum. None of the 7 partial responders pretreated with taxol had responded to it. The overall median survival was 11 months. Neutropenia G4 was reported in 18 patients (42%) with hospitalisation because of febrile neutropenia in 3 of them. Conclusions: In patients with ovarian cancer failing at least 2 previous therapies including platinum, the combination of ifosfamide and mitoxantrone has shown an antitumour activity comparable to that of paclitaxel, with acceptable toxicity. Objective responses were reported also in patients failing paclitaxel, suggesting a lack of cross resistance.

Original languageEnglish
Pages (from-to)419-421
Number of pages3
JournalAnnals of Oncology
Issue number4
Publication statusPublished - Apr 1996


  • Ifosfamide
  • Mitoxantrone
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Salvage therapy with ifosfamide and mitoxantrone in advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this